Call Us for Support
+91 9654860915
Google Reviews
4.8
Call Us for Support
+91 9654860915
Sourced directly from the authorized manufacturer network to ensure authenticity and quality.
You can also access detailed information by clicking Login in the website header.
Supplied with complete CDSCO-approved import and customs documentation, including Form 12A & 12B, CDEC, GST Bill of Entry, Commercial Invoice, and Packing List.
Manufacturer / Innovator:
USA
Regulatory Approval:
N/A
Your Trustedworthy Partner For Named Patient Program
Over a decade of trusted expertise in Named Patient Access to innovative and life-saving medicines.
100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.
Medicines sourced from authorized manufacturers with full batch traceability.
EU-GDP compliant warehousing for secure, quality-controlled global distribution.
Temperature-controlled logistics ensuring safe, reliable, and timely medicine delivery.
Tafinlar (dabrafenib) is a kinase inhibitor approved for multiple BRAF V600-mutated cancers, including unresectable or metastatic melanoma as a single agent, and in combination with trametinib (Mekinist) for melanoma (including adjuvant treatment), metastatic non-small cell lung cancer, anaplastic thyroid cancer, and unresectable or metastatic solid tumors and low-grade glioma in pediatric patients one year and older.
Tafinlar selectively inhibits mutated BRAF kinase (V600E and V600K variants), blocking abnormal signaling in the MAPK pathway that drives tumor growth in cancers carrying this specific genetic mutation.
Tafinlar is used across multiple BRAF V600-mutated cancer types, in both adult and pediatric populations depending on the specific indication, always requiring confirmation of the BRAF mutation through appropriate testing.
The recommended adult dose of Tafinlar is 150 mg (two 75 mg capsules) taken orally twice daily, at least one hour before or two hours after a meal, generally in combination with trametinib depending on the specific indication.
Tafinlar does not carry a formal FDA boxed warning. However, patients and prescribers should be aware of the following important safety information.
New primary malignancies, both cutaneous (such as squamous cell carcinoma) and non-cutaneous, can occur. Regular skin examinations are recommended before and during treatment.
BRAF mutation status should be confirmed before starting Tafinlar, as it can accelerate tumor growth in cancers without a BRAF V600 mutation.
Serious bleeding events have been reported. Left ventricular ejection fraction should be assessed before and periodically during treatment to monitor for cardiomyopathy.
Eye inflammation (uveitis) and severe skin reactions, including Stevens-Johnson syndrome, have been reported and require prompt evaluation.
Blood glucose should be monitored, particularly in diabetic patients. Tafinlar may cause fetal harm, and effective contraception should be used during treatment.
Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.
Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.
Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.
Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.
Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant conditions to maintain product integrity.
Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.
Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.
Tafinlar is manufactured and marketed by Novartis Pharmaceuticals Corporation. It is sourced through authorized distribution channels for patients seeking named-patient import into India. Tafinlar is often prescribed alongside Mekinist (trametinib) as part of a combination regimen.
Patients typically need a valid prescription from a treating oncologist confirming cancer diagnosis and BRAF V600 mutation testing results. NPP's regulatory team assists in preparing and verifying the documentation needed for a compliant import.
As an FDA-approved therapy for BRAF V600-mutated cancers, Tafinlar is sourced through authorized channels and imported under GDP-compliant logistics to preserve product quality throughout transit.
NPP sources Tafinlar directly from authorized pharmaceutical distributors to ensure product authenticity and full traceability. Every shipment is handled under Good Distribution Practice (GDP) conditions from origin to the patient's doorstep.
Tafinlar should be stored at 20°C to 25°C, with excursions permitted between 15°C and 30°C, and this condition is maintained throughout transit.
Once documentation and regulatory approvals are in place, delivery timelines are communicated transparently at the time of quotation, accounting for import clearance and last-mile logistics to the patient's city.
Patients across India can access Tafinlar through NPP's regulated import pathway, with oncology specialists in major cities supporting the treatment process.
Leading hospitals in Mumbai support oncology care coordination and documentation for Tafinlar access.
Delhi's major hospitals assist patients with prescription support and documentation for Tafinlar.
Bangalore's specialist network offers access coordination for eligible BRAF-mutated cancer patients seeking Tafinlar.
Chennai-based oncology specialists coordinate Tafinlar access alongside comprehensive combination-regimen care.
Hyderabad's care institutions support patients pursuing Tafinlar therapy.
Kolkata's specialist centers help coordinate documentation and treatment access for Tafinlar.
Pune-based specialists assist with prescription support and Tafinlar treatment planning.
Ahmedabad's specialty hospitals support the import and treatment process for Tafinlar.
Kochi's specialist units assist patients with the documentation needed for Tafinlar access.
Chandigarh's care centers support Tafinlar treatment coordination for patients from North India.
Jaipur's specialists help patients navigate the Tafinlar access process.
Lucknow-based centers assist patients pursuing Tafinlar therapy.
Bhubaneswar's institutions support access to Tafinlar for eligible patients.
Guwahati's specialists help coordinate Tafinlar access for patients across the Northeast.
Patients in other cities across India can also access Tafinlar through NPP's nationwide coordination network.
Written By: Nitin Goswami, Senior Medical Content Writer
Last Updated: 15 September 2026
Sources: FDA
Medically Reviewed By: Shilpi Banerjee, Registered Pharmacist (M.Pharm)
Last Updated: 15 September 2026
Our specialists are here to guide you through every step of the medicine access process.
Mail Us At:
info@namedpatientprogram.comContact Us:
+91 9654860915Send us a message
